BIOSPECIFICS TECHNOLOGIES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2009-12-17: Form 8-K; Period of report 2009-12-16; Description 8.01 Other Events; Details 8.01.
- 2009-12-01: Form 8-K; Period of report 2009-12-01; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2009-11-09: Form 8-K; Period of report 2009-11-06; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2009-11-05: Form 8-K; Period of report 2009-11-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2009-12-17 | 8-K | 2009-12-16 | 8.01 Other Events | 8.01 A press release regarding the announcement is attached hereto as Exhibit 99.1. | btcf8k121609.htm |
| 2009-12-01 | 8-K | 2009-12-01 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors in December 2009. | bstc120109form8k.htm |
| 2009-11-09 | 8-K | 2009-11-06 | 7.01 Regulation FD Disclosure | 7.01 Commencing November 9, 2009, our President, Thomas L. Wegman, will present to various investors using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | bstc110609form8k.htm |
| 2009-11-05 | 8-K | 2009-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2009, the Company announced its financial and operating results for the fiscal quarter ended September 30, 2009. | bstc110509form8k.htm |
| 2009-09-29 | 8-K | 2009-09-29 | 8.01 Other Events | 8.01 Our President, Thomas L. Wegman, will present to various investors in October 2009. | bstc092909form8k.htm |
| 2009-09-17 | 8-K | 2009-09-16 | 8.01 Other Events | 8.01 On September 16, 2009, the Arthritis Advisory Committee appointed by the Division of Anesthesia, Analgesia and Rheumatology Products of the U.S. Food and Drug Administration (the "FDA") recommended by a unanimous vote of 12 to 0 that XIAFLEX™ be granted marketing approval by the U.S. Food and Drug Administration for the treatment of Dupuytren’s disease. | bstc091609form8k.htm |
| 2009-09-09 | 8-K | 2009-09-09 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors in September 2009. | bstc090909form8k.htm |
| 2009-08-21 | 8-K | 2009-08-21 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors in September 2009. | btc082009f8k.htm |
| 2009-08-12 | 8-K | 2009-08-12 | 2.02 Results of Operations and Financial Condition | 2.02 On August 12, 2009, the Company announced its financial and operating results for the fiscal quarter ended June 30, 2009. | f8k.htm |
| 2009-07-23 | 8-K | 2009-07-22 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to investors at the upcoming CapStone Investments’ Third Annual Small-Cap Investor Conference on Wednesday, July 29, 2009 in Milwaukee, Wisconsin. | biosp072209form8k.htm |
| 2009-06-29 | 8-K | 2009-06-29 | 1.01 Entry into a Material Definitive Agreement | 1.01 As previously reported, Advance Biofactures Corp. ("ABC", and together, with the Company, the "Tenant"), a wholly owned subsidiary of the Company, and Wilbur St. Corp. (the "Landlord"), entered into a Commercial Lease Agreement on January 30, 1998 (the "Commercial Lease Agreement"), pursuant to which the Landlord leased to ABC the premises located at 35 Wilbur Street, Lynbrook, NY 11563 (the "Premises") for a term of 7 years or until January 31, 2005 and for an annual rental price of $125,000. | biosp062909form8k.htm |
| 2009-06-19 | 8-K | 2009-06-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. | biosp061909form8k.htm |
| 2009-05-11 | 8-K | 2009-05-11 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On May 11, 2009, the Company announced its financial and operating results for the fiscal quarter ended March 31, 2009. 7.01 Our President, Thomas L. Wegman, will present to various investors in May 2009 at specific locations and dates to be scheduled beginning on May 12, 2009. | btc051109form8k.htm |
| 2009-04-29 | 8-K | 2009-04-28 | 8.01 Other Events | 8.01 On April 28, 2009 the Company announced that the U.S. Food and Drug Administration (the "FDA") has accepted the Biologics License Application ("BLA") filed by its partner Auxilium Pharmaceuticals, Inc. ("Auxilium") for the use of XIAFLEX™ for the treatment of Dupuytren’s disease and that the application has been granted Priority Review status, indicating that the FDA is expected to take action on the application by August 28, 2009. | biospec042909f8k.htm |
| 2009-03-31 | 8-K | 2009-03-30 | 2.02 Results of Operations and Financial Condition | 2.02 On March 30, 2009, the Company announced its financial and operating results for the fiscal quarter and full year ended December 31, 2008. | biospec033009f8k.htm |
| 2009-03-17 | 8-K | 2009-03-17 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors in March 2009 at specific locations and dates to be scheduled beginning on March 17, 2009. | bstccorp031609form8k.htm |
| 2009-02-17 | 8-K | 2009-02-16 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors in February 2009 at specific locations and dates to be scheduled beginning on February 16, 2009. | biospecifics021309f8k.htm |
| 2009-02-03 | 8-K | 2009-02-03 | 8.01 Other Events | 8.01 On January 30, 2009, the Company received the $6.375 million payment from Auxilium Pharmaceuticals, Inc. ("Auxilium") owed to the Company in connection with its entry into the Amended and Restated Development and License Agreement with Auxilium on December 11, 2008. | biospecifics8k.htm |
| 2009-01-12 | 8-K | 2009-01-12 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors in January 2009 at specific locations and dates to be scheduled beginning on January 12, 2009. | biospecificsf8k010909.htm |
| 2009-01-06 | 8-K | 2009-01-06 | 8.01 Other Events | 8.01 On January 9, 2009 the Company’s common stock will be listed and commence trading on the Nasdaq Global Market under the symbol "BSTC." A press release announcing this development is being furnished as Exhibit 99.1 hereto. | biospecificsf8k010609.htm |